Peginterferon beta-1a is named as a drug or biological intervention in 2 clinical trials in our USA trial register, none of which are currently recruiting. The lead sponsor is Biogen. Registered phases: Observational and Phase 3. Conditions studied include Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT03958877 | A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis (ClinicalTrials.gov ↗) Multiple Sclerosis, Relapsing-Remitting |
Phase 3 | Active, closed |
| NCT05688436 | A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies (ClinicalTrials.gov ↗) Multiple Sclerosis |
Observational | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Multiple Sclerosis | 1 |
| Multiple Sclerosis, Relapsing-Remitting | 1 |
| Lead sponsor | Trials |
|---|---|
| Biogen | 2 |
| Register | Peginterferon beta-1a trials |
|---|---|
| Clinical trials in USA | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Peginterferon beta-1a works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Peginterferon beta-1a (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.